Market Overview

UPDATE: Jefferies Lowers PT on Pfizer Following Global Pharma Review

Share:
Related PFE
Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE, for Patients with Hormone Receptor–Positive Early Breast Cancer
Alvogen to Acquire Product Portfolio from Pfizer for the U.S. Market, no terms
Stock Market News for August 27, 2015 (Zacks)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), but lowered the price target from $33.00 to $32.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Pfizer closed on Thursday at $27.48.

Latest Ratings for PFE

DateFirmActionFromTo
Aug 2015JefferiesMaintainsBuy
Jun 2015JefferiesInitiates Coverage onOverweight
Jun 2015Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Get Benzinga's Newsletters